185 related articles for article (PubMed ID: 9777974)
1. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
3. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
LeGrand EK
Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
[TBL] [Abstract][Full Text] [Related]
4. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
5. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
7. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
Ladin D
Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
[TBL] [Abstract][Full Text] [Related]
8. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
9. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis.
Mandracchia VJ; Sanders SM; Frerichs JA
Clin Podiatr Med Surg; 2001 Jan; 18(1):189-209, viii. PubMed ID: 11344978
[TBL] [Abstract][Full Text] [Related]
10. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
12. [Becaplermin gel (Regranex gel)].
Senet P
Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
[TBL] [Abstract][Full Text] [Related]
13. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
Boykin JV
Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
Victor-Vega C; Desai A; Montesinos MC; Cronstein BN
Inflammation; 2002 Feb; 26(1):19-24. PubMed ID: 11936752
[TBL] [Abstract][Full Text] [Related]
16. The future of recombinant growth factors in wound healing.
Robson MC; Mustoe TA; Hunt TK
Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
Robson MC; Phillips LG; Thomason A; Robson LE; Pierce GF
Lancet; 1992 Jan; 339(8784):23-5. PubMed ID: 1345953
[TBL] [Abstract][Full Text] [Related]
18. Platelet-derived growth factor-BB (PDGF-BB) in tear fluid: a potential modulator of corneal wound healing following photorefractive keratectomy.
Vesaluoma M; Teppo AM; Grönhagen-Riska C; Tervo T
Curr Eye Res; 1997 Aug; 16(8):825-31. PubMed ID: 9255512
[TBL] [Abstract][Full Text] [Related]
19. Original articles: ease of wound closure as an endpoint of treatment efficacy.
Robson MC; Maggi SP; Smith PD; Wassermann RJ; Mosiello GC; Hill DP; Cooper DM
Wound Repair Regen; 1999; 7(2):90-6. PubMed ID: 10231510
[TBL] [Abstract][Full Text] [Related]
20. Effects of homodimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat.
Lepistö J; Laato M; Niinikoski J; Lundberg C; Gerdin B; Heldin CH
J Surg Res; 1992 Dec; 53(6):596-601. PubMed ID: 1494293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
